Sanofi Enters a ~$1.84B Global License Agreement with Earendil Labs for HXN-1002 & HXN-1003

Shots:

• Earendil Labs has granted Sanofi exclusive global rights to develop HXN-1002 & HXN-1003 bispecific antibodies for autoimmune & inflammatory bowel diseases
• As per the deal, Earendil Labs will receive $125M upfront, ~$1.72B in development & commercial milestones, incl. a near-term $50M payment, & tiered royalties ranging from high-single to low-double digits
• Developed using Earendil Labs’ AI discovery & research platform, HXN-1002 targets α4β7 & TL1A to treat mod. to sev. UC & Crohn’s disease, while HXN-1003 inhibits TL1A & IL-23 pathways, showing synergistic efficacy in preclinical colitis & skin inflammation models   

Ref: Prnewswire | Image: Sanofi 

Related News:- Sanofi Licenses an Undisclosed Nurix Therapeutics’ Drug Program for Autoimmune Diseases

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com